Moberg Pharma’s distribution agreement with the Menarini Group – a top 40 global pharmaceutical company – includes Italy, China and eight countries in Southeast Asia. In addition to China, launch activities have previously been initiated in Malaysia, Singapore and Hong Kong. Preparations are ongoing in the other markets in the region.
"We are very pleased with the progress and that the launch of Kerasal Nail now has started in China. Kerasal Nail has significant potential in the region. Assuming successful launches, we expect the region to become an important contributor to revenues and earnings from 2015 and onwards," said Peter Wolpert, CEO of Moberg Pharma AB.
Moberg Pharma is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the US and a distributor network in more than 40 countries.
The company’s portfolio includes the OTC brands Kerasal, Kerasal Nail, Balmex, Jointflex, Domeboro, Vanquish, and Fergon. Kerasal Nail (Emtrix or Nalox in certain ex-U.S. markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia.
The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two phase II assets, MOB-015 (onychomycosis) and BUPI (oral mucositis).
Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).